ProCE Banner Activity

Optimizing Outcomes in Older Patients With HBV

Slideset Download
Read expert faculty member summaries of key data in older patients with HBV, including HBV and HDV epidemiology, treatment criteria, risk of liver complications, the influence of comorbidities on treatment decisions, and treatment considerations for HBV and HDV.

Released: November 16, 2022

Expiration: November 15, 2023

Begin Activity

Share

Faculty

Graham R. Foster

Graham R. Foster, FRCP, PhD

Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Graham R. Foster, FRCP, PhD

Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Graham R. Foster, FRCP, PhD: consultant: AbbVie, Biogen, Gilead, GlaxoSmithKline, MSD, UniQure.

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD: consultant/advisor: AbbVie, Antios, Arbutus, Gilead, Intercept, Salix; researcher: AbbVie, Gilead, Intercept.